ES8304797A1 - "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas". - Google Patents

"procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas".

Info

Publication number
ES8304797A1
ES8304797A1 ES513235A ES513235A ES8304797A1 ES 8304797 A1 ES8304797 A1 ES 8304797A1 ES 513235 A ES513235 A ES 513235A ES 513235 A ES513235 A ES 513235A ES 8304797 A1 ES8304797 A1 ES 8304797A1
Authority
ES
Spain
Prior art keywords
acid
dipyridamole
host
addition salt
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES513235A
Other languages
English (en)
Spanish (es)
Other versions
ES513235A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6134913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8304797(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Publication of ES513235A0 publication Critical patent/ES513235A0/es
Publication of ES8304797A1 publication Critical patent/ES8304797A1/es
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES513235A 1981-06-19 1982-06-18 "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas". Expired ES8304797A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19813124090 DE3124090A1 (de) 1981-06-19 1981-06-19 Neue orale dipyridamolformen

Publications (2)

Publication Number Publication Date
ES513235A0 ES513235A0 (es) 1983-03-16
ES8304797A1 true ES8304797A1 (es) 1983-03-16

Family

ID=6134913

Family Applications (1)

Application Number Title Priority Date Filing Date
ES513235A Expired ES8304797A1 (es) 1981-06-19 1982-06-18 "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas".

Country Status (27)

Country Link
US (1) US4427648A (enExample)
EP (1) EP0068191B2 (enExample)
JP (1) JPS5849312A (enExample)
KR (1) KR880001090B1 (enExample)
AR (1) AR228779A1 (enExample)
AT (1) ATE17317T1 (enExample)
AU (1) AU555951B2 (enExample)
CA (1) CA1200496A (enExample)
DD (1) DD202505A5 (enExample)
DE (2) DE3124090A1 (enExample)
DK (1) DK158540C (enExample)
ES (1) ES8304797A1 (enExample)
FI (1) FI80829C (enExample)
GB (1) GB2101484B (enExample)
GR (1) GR76503B (enExample)
HU (1) HU186078B (enExample)
IE (1) IE53543B1 (enExample)
IL (1) IL66075A (enExample)
IN (1) IN158513B (enExample)
MA (1) MA19503A1 (enExample)
MX (1) MX160712A (enExample)
MY (1) MY8700727A (enExample)
NZ (1) NZ201008A (enExample)
PH (1) PH25637A (enExample)
PT (1) PT75077B (enExample)
SU (1) SU1151193A3 (enExample)
ZA (1) ZA824315B (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2470599A1 (fr) * 1979-12-07 1981-06-12 Panoz Donald Perfectionnements apportes aux procedes de preparation de formes galeniques a action retard et a liberation programmee et formes galeniques de medicaments ainsi obtenus
DE3237575A1 (de) * 1982-10-09 1984-04-12 Dr. Karl Thomae Gmbh, 7950 Biberach Neue orale mopidamolformen
KR880002139B1 (ko) * 1983-04-08 1988-10-17 베링거 인겔하임 리미티드 경구 투여용 정제의 제조방법
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
DE3320582A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Gliquidonhaltige zubereitungsformen und verfahren zu ihrer herstellung
JPS6051106A (ja) * 1983-08-31 1985-03-22 Yamanouchi Pharmaceut Co Ltd 塩酸アモスラロ−ル持続性製剤
US4867984A (en) * 1984-11-06 1989-09-19 Nagin K. Patel Drug in bead form and process for preparing same
CA1323833C (en) * 1987-04-28 1993-11-02 Yatindra M. Joshi Pharmaceutical compositions in the form of beadlets and method
GB8813032D0 (en) * 1988-06-02 1988-07-06 Boehringer Ingelheim Int Antiviral pharmaceutical composition
US5064656A (en) * 1989-11-14 1991-11-12 Dr. Gergely & Co. Uncoated pharmaceutical reaction tablet
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US5364646A (en) * 1990-01-10 1994-11-15 Dr. Karl Thomae Gmbh Oral pharmaceutical forms of pimobendan
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
AU2016992A (en) * 1991-05-20 1992-12-30 Marion Laboratories, Inc. Multi-layered controlled release formulation
US5302393A (en) * 1991-07-11 1994-04-12 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Method for inhibiting biological degradation of implantation polymeric material, inhibitor thereof and implantation polymeric material containing the inhibitor
US5270047A (en) * 1991-11-21 1993-12-14 Kauffman Raymond F Local delivery of dipyridamole for the treatment of proliferative diseases
DE19845358A1 (de) 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
EP1093814A1 (en) * 1999-10-22 2001-04-25 Boehringer Ingelheim Pharma KG Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrin-dependent microcirculation disorders
US7064130B2 (en) * 2001-04-20 2006-06-20 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of radical-scavenging compounds for treatment and prevention of NO-dependent microcirculation disorders
DE10149674A1 (de) 2001-10-09 2003-04-24 Apogepha Arzneimittel Gmbh Orale Darreichungsformen für Propiverin oder seinen pharmazeutisch annehmbaren Salzen mit verlängerter Wirkstoffreisetzung
JP4331930B2 (ja) * 2001-10-17 2009-09-16 武田薬品工業株式会社 酸に不安定な薬物の高含量顆粒
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
JP2006516593A (ja) 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｍｍｐ−９依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
DE10306179A1 (de) 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
RU2005136383A (ru) 2003-04-24 2007-06-10 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1747016A2 (en) * 2004-05-13 2007-01-31 Boehringer Ingelheim International GmbH Use of dipyridamole for treatment of resistance to platelet inhibitors
BG860Y1 (bg) * 2004-09-17 2007-02-28 "Софарма" Ад Лекарствена форма на дипиридамол
WO2006100281A2 (en) 2005-03-22 2006-09-28 Losan Pharma Gmbh Solubilized ibuprofen
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
MX2008002492A (es) * 2005-08-22 2008-04-03 Novartis Ag Composiciones farmaceuticas que comprenden un farmaco dependiente del ph, un modificador del ph, y un agente retardante.
GB0517204D0 (en) * 2005-08-22 2005-09-28 Novartis Ag Organic compounds
BRPI0707324A2 (pt) * 2006-01-27 2011-05-03 Eurand Inc sistemas de fornecimento de fármaco compreendendo agente de bloqueio de serotonina 5-ht3 seletivo fracamente básico e ácidos orgánicos
AU2007211101B2 (en) * 2006-01-27 2013-05-02 Adare Pharmaceuticals, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20070184110A1 (en) * 2006-02-09 2007-08-09 Minutza Leibovici Dipyridamole extended-release formulations and process for preparing same
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
KR101451564B1 (ko) 2007-12-28 2014-11-04 임팩스 라보라토리즈, 인코포레이티드 레보도파 방출 제어형 제제 및 이의 용도
WO2009097156A1 (en) * 2008-02-01 2009-08-06 Barr Laboratories, Inc. Pharmaceutical capsules comprising extended release dipyridamole pellets
US8133506B2 (en) * 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
US20100080846A1 (en) * 2008-09-25 2010-04-01 Avshalom Ben-Menachem Dipyridamole and acetylsalicylic acid formulations and process for preparing same
US20110003005A1 (en) * 2009-07-06 2011-01-06 Gopi Venkatesh Methods of Treating PDNV and PONV with Extended Release Ondansetron Compositions
WO2011014741A1 (en) * 2009-07-31 2011-02-03 Artemis Health, Inc. Methods and compositions for cell stabilization
EP2361615A1 (en) 2010-02-19 2011-08-31 Alfred E. Tiefenbacher GmbH & Co. KG Dipyridamole prolonged-release tablet
EA201391758A1 (ru) * 2011-05-24 2014-06-30 Тева Фармасьютикал Индастриз Лтд. Спрессованная сердцевина для фармацевтической композиции, содержащая органические кислоты
WO2013135852A1 (en) 2012-03-15 2013-09-19 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
HRP20251029T1 (hr) 2013-07-19 2025-10-24 Boehringer Ingelheim Vetmedica Gmbh Konzervirani eterificirani derivati ciklodekstrina koji sadrže tekući vodeni farmaceutski pripravak
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
ES2823000T3 (es) 2013-10-07 2021-05-05 Impax Laboratories Llc Formulaciones muco-adhesivas de liberación controlada de levodopa y/o ésteres de levodopa y usos de las mismas
MX375936B (es) 2013-12-04 2025-03-07 Boehringer Ingelheim Vetmedica Gmbh Composiciones farmaceuticas mejoradas de pimobendan.
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EP4267113A4 (en) 2020-12-22 2025-02-12 Amneal Pharmaceuticals LLC LEVODOPA DOSING SCHEME
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2157201C3 (de) * 1970-11-13 1974-12-12 Boehringer Mannheim Gmbh, 6800 Mannheim Verbesserte feste orale Applikationsform von Raubasin
DE2700433A1 (de) * 1977-01-07 1978-07-20 Kali Chemie Pharma Gmbh Arzneimittelzubereitungen mit verbesserten resorptionseigenschaften
LU77353A1 (enExample) * 1977-05-16 1979-01-19
DD146547A5 (de) * 1978-07-15 1981-02-18 Boehringer Sohn Ingelheim Arzneimittel-retardform mit unloeslichen poroesen diffusionshuellen
DE2950977A1 (de) * 1978-12-22 1980-07-10 Donald E Panoz Neue galenische zubereitungsform fuer die orale verabreichung von medikamenten mit programmierter besetzung, sowie verfahren zu ihrer herstellung
DE3000979A1 (de) * 1980-01-12 1981-07-23 Dr. Karl Thomae Gmbh, 7950 Biberach Neue dipyridamol-retardformen und verfahren zu ihrer herstellung
JPS6116368A (ja) * 1984-07-02 1986-01-24 Mitsubishi Electric Corp 画像処理装置の検査装置

Also Published As

Publication number Publication date
PT75077A (de) 1982-07-01
IL66075A0 (en) 1982-09-30
GR76503B (enExample) 1984-08-10
DE3124090C2 (enExample) 1991-11-21
ES513235A0 (es) 1983-03-16
DK269682A (da) 1982-12-20
GB2101484A (en) 1983-01-19
KR880001090B1 (ko) 1988-06-23
DK158540B (da) 1990-06-05
EP0068191B2 (de) 1991-09-11
SU1151193A3 (ru) 1985-04-15
IE821453L (en) 1982-12-19
DE3124090A1 (de) 1983-01-05
ATE17317T1 (de) 1986-01-15
KR840000229A (ko) 1984-02-18
NZ201008A (en) 1985-11-08
GB2101484B (en) 1984-09-19
MX160712A (es) 1990-04-23
DD202505A5 (de) 1983-09-21
IE53543B1 (en) 1988-12-07
IN158513B (enExample) 1986-11-29
AR228779A1 (es) 1983-04-15
FI80829B (fi) 1990-04-30
FI822173A0 (fi) 1982-06-17
AU8496582A (en) 1982-12-23
MY8700727A (en) 1987-12-31
ZA824315B (en) 1984-02-29
AU555951B2 (en) 1986-10-16
JPS5849312A (ja) 1983-03-23
PT75077B (de) 1985-05-31
DE3268380D1 (en) 1986-02-20
EP0068191A3 (en) 1983-08-10
US4427648A (en) 1984-01-24
IL66075A (en) 1985-09-29
DK158540C (da) 1990-11-12
EP0068191A2 (de) 1983-01-05
JPH0251402B2 (enExample) 1990-11-07
EP0068191B1 (de) 1986-01-08
CA1200496A (en) 1986-02-11
MA19503A1 (fr) 1982-12-31
FI822173L (fi) 1982-12-20
PH25637A (en) 1991-08-21
HU186078B (en) 1985-05-28
FI80829C (fi) 1990-08-10

Similar Documents

Publication Publication Date Title
ES8304797A1 (es) "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas".
ES8500743A1 (es) Procedimiento para preparar formas de mopidamol como granulados, granulos o tabletas
MX9605650A (es) Formulaciones de propionato de fluticasona.
UA27760C2 (uk) Композиція у вигляді наночасток і спосіб її одержання
MX9504034A (es) Formas de administracion medicamentosas que contienen acido tioctico, o sales solidas del acido tioctico de liberacion y biodisponibilidad mejoradas.
SE9701956D0 (sv) New composition of matter
AU4515985A (en) New tetrapyrrole therapeutic agents
GR3031448T3 (en) Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine.
CA2150184A1 (en) Pharmaceutical composition for the treatment of inflammatory bowel diseases
DE19975006I2 (de) Pharmazeutische Zusammensetzungen zur Behandlung gastrointestinaler St¦rungen.
EP0911331A3 (en) Substituted dibenzoxazepine compounds, pharmaceutical compositions and methods of use
EP0169392A3 (en) Triazolobenzodiazepines and pharmaceutical compositions containing them
CA2132544A1 (en) Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
NZ296765A (en) 8-cyclohexyl substituted xanthine derivatives and medicaments
DK484585A (da) Micellulaere partikelkompositioner, hvori er indkapslet billedtagende og kemoterapeutiske midler for tumorer, og kompositionernes anvendelse
DE3380923D1 (de) Pharmazeutische zusammensetzungen zur behandlung von stoerungen, bedingt durch humanendrogen.
WO1994013304A3 (en) Antacid composition and method of production
EP0790250A3 (en) Inhibitors of biogenic amine transporters
EP0348664A3 (en) Pharmaceutical compositions containing monoacetoacetins for treating tumours
DE69736955D1 (de) Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen
PL320996A1 (en) 4,4-(disubstituted) monomers of cyclohexan-1-ol and compounds shoving affinity to them
MX9602846A (es) Compuestos de vanadato para el tratamiento de desordenes proliferativos, metastasis, y tumores resistentes a los farmacos.
CA2183764A1 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration